Atopic dermatitis: dupilumab shows benefit even without skin clearance

  • Silverberg JI & al.
  • Br J Dermatol
  • 21 Feb 2019

  • curated by Brian Richardson, PhD
  • Clinical Essentials
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • Pooled analysis of data from the phase 3 LIBERTY AD SOLO 1 and 2 trials suggests that dupilumab (Dupixent) is associated with clinical benefit by several validated outcome measurements in patients with atopic dermatitis (AD) who did not achieve Investigator’s Global Assessment (IGA) score ≤1 (clear/almost clear skin).

Why this matters

  • IGA score ≤1 is considered the regulatory standard for treatment success in US trials of patients with AD.

Key results

  • In patients with IGA >1, dupilumab was associated with several superior results compared with placebo (P<.001 for all style="list-style-type:circle;">
  • Eczema Area and Severity Index (EASI) improvements (−48.9% vs −11.3%).
  • EASI-50 rates (49.6% vs 16.2%).
  • EASI-75 rates (20.9% vs 4.8%).
  • Pruritus numerical rating scale improvements (−35.2% vs −9.1%).
  • Body surface area affected improvements (−23.1% vs −4.5%).
  • Patient-oriented eczema measure ≥4-point improvement (57.4% vs 21.0%).
  • Dermatology Life Quality Index ≥4-point improvement (59.3% vs 24.4%).
  • Patients rating treatment as good, very good, or excellent (51.5% vs 24.0%).

Study design

  • 674 patients with moderate to severe AD (278 treated with dupilumab every 2 weeks and 396 with placebo) who had IGA >1 at week 16 were included in this analysis.
  • Funding: Sanofi Genzyme; Regeneron Pharmaceuticals, Inc.

Limitations

  • Post hoc analysis.

Please confirm your acceptance

To gain full access to GPnotebook please confirm:

By submitting here you confirm that you have accepted Terms of Use and Privacy Policy of GPnotebook.

Submit